KR102471057B1 - 전이성 결장직장암의 항-혈관신생 치료요법에 관한 예측 및 예후 바이오마커 - Google Patents

전이성 결장직장암의 항-혈관신생 치료요법에 관한 예측 및 예후 바이오마커 Download PDF

Info

Publication number
KR102471057B1
KR102471057B1 KR1020177007326A KR20177007326A KR102471057B1 KR 102471057 B1 KR102471057 B1 KR 102471057B1 KR 1020177007326 A KR1020177007326 A KR 1020177007326A KR 20177007326 A KR20177007326 A KR 20177007326A KR 102471057 B1 KR102471057 B1 KR 102471057B1
Authority
KR
South Korea
Prior art keywords
vegf
patients
aflibercept
biomarker
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177007326A
Other languages
English (en)
Korean (ko)
Other versions
KR20170055972A (ko
Inventor
타샤 니콜 심스
보 가오
이스라엘 로위
Original Assignee
리제너론 파아마슈티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파아마슈티컬스, 인크. filed Critical 리제너론 파아마슈티컬스, 인크.
Publication of KR20170055972A publication Critical patent/KR20170055972A/ko
Application granted granted Critical
Publication of KR102471057B1 publication Critical patent/KR102471057B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G01N33/57419—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020177007326A 2014-09-16 2015-09-10 전이성 결장직장암의 항-혈관신생 치료요법에 관한 예측 및 예후 바이오마커 Active KR102471057B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462051091P 2014-09-16 2014-09-16
US62/051,091 2014-09-16
US201562099630P 2015-01-05 2015-01-05
US62/099,630 2015-01-05
PCT/US2015/049279 WO2016044041A1 (en) 2014-09-16 2015-09-10 Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer

Publications (2)

Publication Number Publication Date
KR20170055972A KR20170055972A (ko) 2017-05-22
KR102471057B1 true KR102471057B1 (ko) 2022-11-28

Family

ID=54207741

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177007326A Active KR102471057B1 (ko) 2014-09-16 2015-09-10 전이성 결장직장암의 항-혈관신생 치료요법에 관한 예측 및 예후 바이오마커

Country Status (12)

Country Link
US (2) US10525104B2 (https=)
EP (1) EP3194974B1 (https=)
JP (1) JP6692358B2 (https=)
KR (1) KR102471057B1 (https=)
CN (1) CN107076749B (https=)
AU (1) AU2015318207B2 (https=)
CA (1) CA2960890A1 (https=)
EA (1) EA036671B1 (https=)
IL (1) IL250905B (https=)
MX (1) MX382673B (https=)
WO (1) WO2016044041A1 (https=)
ZA (1) ZA201701664B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1216765A1 (zh) 2013-03-14 2016-12-02 奥特拉西斯公司 使用所测分析物改进疾病诊断的方法
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
RU2018127709A (ru) 2016-01-22 2020-02-25 Отрэйсис, Инк. Системы и способы улучшения диагностики заболеваний
KR20190131538A (ko) * 2017-03-31 2019-11-26 가부시키가이샤 히로츠 바이오 사이언스 암 환자의 치료 효과의 예측 및/또는 재발 모니터링
FI3743091T3 (fi) 2018-01-26 2025-01-03 Univ California Menetelmät ja koostumukset verisuoniperäisten sairauksien hoitoon käyttämällä anti-vegf vaikuttavia aineita
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
WO2020165483A1 (es) * 2019-02-15 2020-08-20 Universidad de Córdoba Método de predicción de respuesta a tratamiento del cáncer con agentes antiangiogénicos
US20210012899A1 (en) * 2019-07-13 2021-01-14 Otraces, Inc. Diagnosis for various diseases using tumor microenvironment active proteins
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021076852A1 (en) * 2019-10-17 2021-04-22 Board Of Regents, The University Of Texas System Small extracellular vesicle-associated vegf as a predictor for therapeutic responses
WO2021108255A1 (en) 2019-11-25 2021-06-03 The Regents Of The University Of California Long-acting vegf inhibitors for intraocular neovascularization

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013517258A (ja) * 2010-01-19 2013-05-16 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベバシズマブ併用治療のための腫瘍組織に基づくバイオマーカー
JP2013534306A (ja) * 2010-07-19 2013-09-02 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗癌治療への応答可能性の増大した患者を同定する方法
JP2014513089A (ja) * 2011-04-26 2014-05-29 サノフイ アフリバーセプト、フォリン酸、５−フルオロウラシル（５−ｆｕ）及びイリノセタン（フォルフィリ）を含む組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
CN101283280A (zh) * 2005-08-18 2008-10-08 Zadec私人有限公司 用于诊断结直肠癌的蛋白质标记和所述标记作为所述癌症类型治疗的药物靶点的用途
US20110070186A1 (en) * 2009-08-14 2011-03-24 Allergan, Inc. Methods of Treating Cancer Using Growth Factor Retargeted Endopeptidases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013517258A (ja) * 2010-01-19 2013-05-16 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベバシズマブ併用治療のための腫瘍組織に基づくバイオマーカー
JP2013534306A (ja) * 2010-07-19 2013-09-02 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗癌治療への応答可能性の増大した患者を同定する方法
JP2014513089A (ja) * 2011-04-26 2014-05-29 サノフイ アフリバーセプト、フォリン酸、５−フルオロウラシル（５−ｆｕ）及びイリノセタン（フォルフィリ）を含む組成物

Also Published As

Publication number Publication date
EA201790549A1 (ru) 2017-07-31
IL250905B (en) 2019-12-31
AU2015318207A1 (en) 2017-04-06
ZA201701664B (en) 2018-05-30
EP3194974A1 (en) 2017-07-26
US20200129589A1 (en) 2020-04-30
KR20170055972A (ko) 2017-05-22
US11439683B2 (en) 2022-09-13
US20170281725A1 (en) 2017-10-05
CA2960890A1 (en) 2016-03-24
US10525104B2 (en) 2020-01-07
JP2017530372A (ja) 2017-10-12
CN107076749A (zh) 2017-08-18
MX382673B (es) 2025-03-13
EP3194974B1 (en) 2019-10-23
EA036671B1 (ru) 2020-12-07
CN107076749B (zh) 2020-12-29
MX2017003387A (es) 2018-01-30
AU2015318207B2 (en) 2021-11-04
JP6692358B2 (ja) 2020-05-13
IL250905A0 (en) 2017-04-30
WO2016044041A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
KR102471057B1 (ko) 전이성 결장직장암의 항-혈관신생 치료요법에 관한 예측 및 예후 바이오마커
CN110144010B (zh) 阻断型pd-l1驼源单域抗体及其用途
CN113563464B (zh) 人源化高中和活性抗新型冠状病毒单克隆抗体及应用
CA2520097C (en) Truncated baff receptors
KR102057438B1 (ko) 엽산 수용체 알파-발현 암에 대한 진단 및 예후 마커로서의 엽산 수용체 알파
US20040223966A1 (en) ActRIIB fusion polypeptides and uses therefor
CN109053895A (zh) 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
AU2020203110A1 (en) Compositions and methods for treating pulmonary hypertension
CN101102786A (zh) 施用并利用vegf抑制剂治疗人类癌症的方法
KR20200040407A (ko) 신규 항-c-KIT 항체
CN113512113A (zh) 人源化广谱高中和活性抗新型冠状病毒单克隆抗体及应用
US20040265309A1 (en) Method of tumor regression with VEGF inhibitors
KR20110025810A (ko) Ｆｇｆ２１ 돌연변이체 및 그의 용도
CN105384819B (zh) 一种抗人Delta-like 4人源化抗体及其制备与应用
IL179513A (en) Use of an agent inhibiting vascular endothelial growth factor (vegf) activity in the manufacture of a medicament for treating type i diabetes
CN108707198A (zh) 识别人c-Met蛋白的人源单链抗体、诊断试剂及其CAR-T细胞制剂
KR20140004632A (ko) DCC의 제 5 피브로넥틴 유형 III 도메인의 재조합 Fc-융합 단백질
CN106866824A (zh) 一种抗ddx5的全人源单克隆抗体及其制备方法和应用
CN107936118A (zh) 一种抗体‑海兔毒素偶联物及其制备方法和应用
CN109206522B (zh) 一种长效抗凝血融合蛋白及其应用
CN101003575A (zh) 人肿瘤坏死因子可溶性受体Ⅱ－抗体Fc段融合蛋白
CN113234168B (zh) 一种融合蛋白、基因及应用
JPH0977800A (ja) 融合蛋白質、並びに落葉状天疱瘡の治療薬、治療器具、診断剤及び抗体測定方法
CN110904133B (zh) 用于协同解除t细胞衰竭的组合物及应用
CN114426577B (zh) 人源化广谱抗新型冠状病毒单克隆抗体及应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000